Released on: June 10, 2008, 6:19 am

Press Release Author: The Scott Partnership

Industry:

Press Release Summary: (June 10, 2008) Biotage, a leading supplier of tools and
technology for
medicinal and analytical chemistry, announces that it will sponsor summer
programs at the University of Richmond, VA, US from 21-23 July, 2008 and at
the University of Edinburgh, UK, from 29-31 July, 2008. The programs,
entitled \'Application of Modern Tools in Organic Synthesis\', last three days
each and are ideal for newly-qualified discovery chemists and academics
looking to learn about the latest practical approaches for rapid production
of novel compounds. Biotage allows chemists to register and attend this
unique program at a reduced rate through Biotage sponsorship.

Press Release Body: News release
Contact:
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com

Biotage to Host US and UK Summer Program on the Application of Modern Tools
in Organic Synthesis

(June 10, 2008) Biotage, a leading supplier of tools and technology for
medicinal and analytical chemistry, announces that it will sponsor summer
programs at the University of Richmond, VA, US from 21-23 July, 2008 and at
the University of Edinburgh, UK, from 29-31 July, 2008. The programs,
entitled \'Application of Modern Tools in Organic Synthesis\', last three days
each and are ideal for newly-qualified discovery chemists and academics
looking to learn about the latest practical approaches for rapid production
of novel compounds. Biotage allows chemists to register and attend this
unique program at a reduced rate through Biotage sponsorship.

The three-day summer programs in Edinburgh and Richmond will bring together
industry and academic leaders and facilitate discussion on issues such as
solid-bound reagents and scavengers in microwave synthesis,
microwave-accelerated metal-catalyzed transformations, improved efficiency
integrating synthesis and purification, and flow synthesis.

Throughout the programs, leading figures from academic institutions and
commercial organizations including GlaxoSmithKline, Pfizer, Merck, Abbott,
Edinburgh University, Biotage, The Scripps Research Institute and the
University of California will present a series of lectures on
solid-supported reagents and scavengers in microwave synthesis, catalyst
removal and reaction work-up solutions. Presentations will include
\'Combining Solid Phase and Microwave Chemistry\' by Professor Mark Bradley of
the University of Edinburgh, and \'Enhanced Chemical Synthesis Using Flow
Reactors\' by Dr Paul Watts of the University of Hull.

Interactive workshops will focus on streamlining workflows with microwave
and flash purification systems, scavengers, reagents and reaction work-up
products. In addition to a wide range of lectures and practical workshops,
delegates are encouraged to take part in poster sessions. Posters describing
a range of organic synthesis applications will be on display throughout the
program, encouraging knowledge sharing and interaction.

For more information on the Biotage summer programs and to register, please
contact emma.daughton@eu.biotage.com (UK) or natalie.gay@biotage.com (US) or
visit www.biotage.com.

-ENDS-
For further press information please contact: Eleanor CallanMonk, The Scott
Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel:
+44 1477 539539 Fax: +44 1477 539540 e-mail: biotage@scottpr.com

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the
market. The company offers solutions, knowledge and experience in the areas
of genetic analysis and medicinal chemistry. In 2005 operations and products
were acquired from the American company Argonaut, further strengthening the
medicinal chemistry product range. The customers include the worlds top 30
pharmaceutical companies, the worlds top 20 biotech companies, and leading
academic institutes. The company is headquartered in Uppsala and has offices
in the U.S., Japan, UK, Germany and several other European countries.
Biotage has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is
listed on the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com

Certain statements in this press release are forward-looking. These may be
identified by the use of forward-looking words or phrases such as \"believe,\"
\"expect,\" \"intend,\" and \"should,\" among others. These forward-looking
statements are based on Biotage\'s current expectations. The Private
Securities Litigation Reform Act of 1995 provides a \"safe harbor\" for such
forward-looking statements. In order to comply with the terms of the safe
harbor, Biotage notes that a variety of factors could cause actual results
and experience to differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. Such
uncertainties and risks include, but are not limited to, risks associated
with management of growth and international operations (including the
effects of currency fluctuations), variability of operating results, the
commercial development of the microwave synthesis and flash purification in
the drug discovery market, DNA sequencing and genomics market, nucleic
acid-based molecular diagnostics market, and genetic vaccination and gene
therapy markets, competition, rapid or unexpected changes in technologies,
fluctuations in demand for Biotage\'s products (including seasonal
fluctuations), difficulties in successfully adapting the Company\'s products
to integrated solutions and producing such products, and the Company\'s
ability to identify and develop new products and to differentiate its
products from competitors.



Web Site: http://

Contact Details: Contact:
Jennifer Whedbee, Director Marketing Communications
Tel: +1 434 220 2652, jwhedbee@biotage.com